Lecture 12: Acquired Valvular and Endocardial Disease

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/54

encourage image

There's no tags or description

Looks like no tags are added yet.

55 Terms

1
New cards

acquired valvular and endocardial heart disease

  • myxomatous degeneration

  • infectious endocarditis

  • neoplastic


2
New cards

causes of mitral valve regurgitation

  • myxomatous mitral valve disease (MMVD)

  • DCM/HCM/RCM

  • mitral valve endocarditis

  • congenital mitral dysplasia


3
New cards

diagnostic approach to acquired valvular and endocardial heart disease

  • auscultation of a murmur

  • remainder of cardiovascular exam

  • ECG

  • thoracic radiographs

  • echocardiography


4
New cards

myxomatous mitral valve disease (MMVD)

  • also called endocardiosis, degeneration MV disease, chronic valvular disease

  • thickening and elongation of the valve leaflets, leads to valvular insufficiency and volume overload of the left atrium and ventricle

  • 75-80% of all canine heart disease

  • smaller dogs <45 lbs and older dogs

  • males 1.5x more likely than females

  • disease progresses slowly

  • cause unclear


5
New cards

early MMVD

asymptomatic; incidental left apical systolic murmur

6
New cards

progressive MMVD

cough, exercise intolerance, tachypnea, restlessness

7
New cards

CHF with MMVD

dyspnea, syncope, collapse, ± ascites

8
New cards

MMVD PE

  • left apical systolic murmur

  • ± tachycardia, arrhythmia, dyspnea, crackles, weak pulses


9
New cards

MMVD ECG

± sinus tachycardia, arrhythmias, large LA/LV patterns

10
New cards

MMVD thoracic radiographs

  • cardiomegaly over time (LA), with L bronchus compression

  • LAA bulge at 3:00 on DV

  • lateral projection → tracheal elevation and left atrial bulge caudodorsal aspect of heart

  • pulmonary venous congestion

  • interstitial to alveolar pattern if CHF


11
New cards
<p>what is this?</p>

what is this?

MMVD

12
New cards

MMVD echocardiography

  • thickened mitral leaflets

  • mitral valve prolapse

  • mitral regurgitation ± tricuspid regurgitation

  • LV volume overload → LV, LA dilation

  • La:Ao ratio > 1.6 is significant


13
New cards
<p>what is this showing?</p>

what is this showing?

MMVD → large LA

14
New cards
<p>what is the yellow arrow showing?</p>

what is the yellow arrow showing?

ruptured chordae tendinae

15
New cards

typical presentation of ruptured chordae tendinae

acute LCHF

16
New cards
<p>what are these showing?</p>

what are these showing?

ruptured chordae tendinae → acute LCHF

17
New cards

MMVD clinical syndromes

  • no clinical signs

  • cough → left main bronchus compression, early CHF

  • left sided congestive heart failure

  • ruptured chordae tendinae (acute LCHF)

  • syncope

  • endocardial split/LA tear → cardiac tamponade


18
New cards

MMVD lab testing

  • if starting ACE inhibitor → kidney values, electrolytes

  • if starting diuretics → kidney values, electrolytes, PCV/total solids

  • some dogs are also hypertensive

  • NT-proBNP → stage disease severity, predict imminent CHF, diagnose CHF


19
New cards

what are the big 4 for MMVD therapy?

  • furosemide

  • spironolactone

  • pimobendan

  • ACE inhibitor


20
New cards

new combo therapy for MMVD

  • cardalis

  • spironolactone/benazepril combination

  • for management of congestive heart failure in dogs

  • chewable tablets, 3 strengths


21
New cards

takeaways from ACVIM consensus statement

  • stage all MMVD patients

  • pimobendan in stage B2

  • spironolactone in CHF


22
New cards

ACVIM stage 1

dogs at higher than average risk for developing heart failure but without any apparent structural abnormality (no murmur etc)

23
New cards

diagnosis of stage A

  • small breed dogs should undergo regular evaluations

  • owners of breeding dogs or those at high risk (Cavaliers) may choose to participate in yearly screening events and conducted by board-certified cardiologists


24
New cards

stage A treatment

  • no drug treatment recommended

  • no dietary treatment recommended

  • potential breeding animals should no longer be bred if a murmur or echocardiographic evidence of mitral regurgitation is identified early


25
New cards

ACVIM stage B

structural abnormality (ie MMVD) but no clinical signs of heart failure

26
New cards

ACVIM stage B1

asymptomatic dogs with MV regurgitation from MMVD not severe enough to meet criteria used to trigger treatment

27
New cards

ACVIM stage B2

asymptomatic dogs with MV regurgitation from MMVD severe enough to result in cardiac remodeling (LA/LV enlargement) sufficient to recommend treatment

28
New cards

diagnosis for stage B2 criteria

  • murmur intensity >3/6

  • echocardiographic LA:Ao ratio > 1.6

  • left ventricular internal diastole diameter > 1.7

  • breed-adj radiographic vertebral heart score > 10.5


29
New cards

stage B1 treatment

  • no drug or dietary treatment is recommended

  • reeval by echocardiography or radiography in 6-12 months


30
New cards

stage B2 treatment

  • pimobendan at a dosage of 0.25-0.3mg/kg

  • diet → mild sodium restriction, adequate protein/calories, highly palatable

  • angiotensin converting enzyme inhibitors (ACEI)

  • beta blockade is not recommended routinely

  • spironolactone is not recommended for routine use to delay the onset of heart failure in dogs

  • cough suppressants (maybe)

  • surgical intervention (maybe)


31
New cards

ACVIM stage C

  • MMVD severe enough to cause current or past clinical signs of heart failure

  • hospitalized (acute) vs home (chronic)


32
New cards

diagnosis of stage C

  • ECG, thoracic radiographs, echocardiogram, NT-proBNP

  • normal/near normal [NT-proBNP] in dog with cough, dyspnea, or exercise intolerance = not CHF


33
New cards

treatment for stage C hospital/acute

furosemide, oxygen, pimobendan, sedation PRN, centesis PRN, nursing care, dobutamine/sodium nitroprusside/ACEi/nitroglycerin all PRN

34
New cards

treatment for stage C home/chronic

  • furosemide, pimobendan, ACEi, spironolactone

  • cough suppressants/bronchodilators

  • continue diet per stage B, promote appetite PRN, adjust K/Mg PRN

  • monitor BUN/Cr/lytes

  • increase in resting RR above normal has best predictive value for impending clinical decompensation


35
New cards

ACVIM stage D

patients have clinical signs of failure refractory to standard treatment for stage C heart failure from MMVD

36
New cards

treatment for stage D hospital/acute

  • furosemide higher dose or torsemide

  • centesis PRN, more potent afterload reduction

  • sildenafil PRN is pulmonary hypertension


37
New cards

treatment for stage D home/chronic

  • furosemide/torsemide, hydrochlorothiazide, pimobendan, ACEi, spironolactone

  • continue diet per stage B, promote appetite PRN

  • monitor BUN/Cr/lytes

  • increase in resting respiratory rate above normal baseline has the best predictive value for impending clinical decompensation


38
New cards

prognosis and survival for stage B1

years, may never progress

39
New cards

prognosis and survival for stage B2

3.5 years to CHF with pimobendan

40
New cards

prognosis and survival for stage C

6-12 months

41
New cards

prognosis and survival for stage D

weeks to months

42
New cards

mitral valve repair surgery (open-heart surgery)

  • requires cardiopulmonary bypass

  • available only at specialized centers

  • can be curative with survival often exceeding 3-5 years

  • high cost and requires intensive post-op care


43
New cards

transcatheter edge-to-edge repair (TEER/mitral clip)

  • minimally invasive catheter technique inspired by human mitraclip

  • clips anterior and posterior mitral valve leaflets to reduce regurgitation

  • still experimental in vet med

  • promising for dogs unfit for open surgery


44
New cards

transcatheter mitral valve replacement (TMVR)

  • experimental use of catheter-based prosthetic valve replacement

  • challenges include anchoring the valve and anatomical variability

  • currently limited to research environments


45
New cards

stem cell and gene therapy (research phase)

  • mesenchymal stem cells reduce inflammation and fibrosis

  • gene therapy targets collagen remodeling and TGF-beta signaling


46
New cards

bacterial endocarditis

  • infective endocarditis, vegetative endocarditis

  • bacterial infection of the endocardium → valvular endocarditis is most common

  • low incidence

  • infection leads to thickening/fibrous valvular changes


47
New cards

risk factors of bacterial endocarditis

  • pre-existing valvular disease

  • immunosuppressive drugs

  • middle aged, intact male large breed dogs

  • recent surgery

  • recent IV catheter placement

  • antimicrobial use

  • allergic factor


48
New cards

cardiac effects of bacterial endocarditis

  • mitral valve → mitral regurgitation, mitral stenosis, left sided CHF

  • aortic valve → aortic regurgitation, aortic stenosis, left sided CHF

  • pulmonic and tricuspid valve → tricuspid and/or pulmonic stenosis or insufficiency, right sided CHF, pulmonary thromboembolism


49
New cards

systemic effects from bacterial endocarditis

  • pyelonephritis

  • UTI

  • meningitis

  • septic arthropathy

  • myocarditis

  • immune mediated GN or polyarthritis

  • thrombosis can lead to infection or infarction (bland thrombus)


50
New cards

clinical scenarios for bacterial endocarditis

  • congestive heart failure

  • fever of unknown origin

  • multisystemic signs suggestive of infection or immune-mediated disease

  • organ embolism


51
New cards

common clinical findings of bacterial endocarditis

  • fever

  • leukocytosis

  • cardiac murmur

  • lameness

  • lethargy, anorexia, depression


52
New cards

diagnostic testing for bacterial endocarditis

  • bartonella testing

  • arthrocentesis → cytology and culture

  • blood and urine cultures


53
New cards

echocardiographic findings for bacterial endocarditis

  • thick, asymmetric, shaggy, hyperechoic vegetative valvular lesions

  • oscillating, vibratory, or mobile valvular lesions

  • cardiac chamber enlargement or hypertrophy

  • valvular regurgitation or stenosis

  • transesophageal echocardiography


54
New cards

treatment for bacterial endocarditis

  • antibiotic based on culture and sensitivity or serology

  • IV antibiotics for the first 5-14 days

  • broad spectrum antibiotics → ampicillin and enrofloxacin most common

  • suspicion of bartonella spp. → doxy and gentamicin or enrofloxain in dogs, doxy and pradofloxacin in cats

  • additional anaerobic coverage → clindamycin or metro

  • oral antibiotics for 4 to 8 weeks


55
New cards

prognosis and prevention for bacterial endocarditis

  • median survival 2 months

  • aortic valve 3 days vs mitral vale 476 days

  • worse prognosis if → CHF present, aortic valve affected, gram negative sepsis, renal failure, thrombocytopenia, thromboembolic complications, azotemia, treated with corticosteroids

  • prevention → prophylactic antibiotics in susceptible patients, human guidelines